Using mouse osteoclast-like cells (OCs), we have shown that short exposure to calcitonin (CT) resulted in prolonged reduction of CT binding by inhibiting de novo CT receptor (CTR) synthesis. Additionally, CT-treated OCs demonstrated resistance to CT rechallenge on the inhibitory effect of CT in osteoclastic bone resorption. There is, however, scant information on CT effects on human osteoclasts. In this study, we examined the features of CTR down-regulation and its recovery after short exposure to CT of human OCs. OCs were prepared by treatment of peripheral blood mononuclear cells in vitro with osteoclast differentiation factor and macrophage colony-stimulating factor. Treatment of OCs with salmon CT (sCT) and human CT (hCT) resulted in a dose-dependent reduction in [
l]sCT-specific binding for a prolonged period, as we have shown previously in mouse OCs. The reduced specific binding, CTR messenger RNA levels, and CT-sensitive adenylate cyclase responsiveness returned to the control levels by 96 h after removal of CT. These results strongly support the notion that escape from CT inhibition of osteoclastic bone resorption in humans is attributable to the development of resistance by OCs to CT. This study also showed that even short exposure to CT induced prolonged desensitization to CT rechallenge, although the OCs eventually regained responsiveness to sCT rechallenge. (Endocrinology 141: 3774 -3782, 2000) C ALCITONIN (CT) directly inhibits osteoclastic bone resorption and is widely used to treat metabolic bone disorders, such as Paget's disease of bone, malignancyassociated hypercalcemia, and osteoporosis (1) (2) (3) . It is recognized, however, that continuous treatment with CT eventually causes a loss of its inhibitory effects on osteoclastic bone resorption. We and other investigators have studied the mechanism of this escape phenomenon, mostly using mouse and rat osteoclasts (4 -6) . The results indicated that escape or desensitization to CT was closely associated with the downregulation of the CT receptor (CTR). This down-regulation was caused not only by internalization of the receptor (5) but also by reduced cell surface receptor expression through inhibition of de novo CTR synthesis (6, 7) . The intracellular signaling responsible for the process of CT-induced homologous CTR down-regulation in mouse osteoclast-like cells (OCs) was activation of the protein kinase (PK)A pathway through cell surface CTR (8) . There is, however, scant information on CTR regulation and the mechanism of homologous desensitization to CT, in cells of osteoclast lineage in other species, because of the difficulties in obtaining sufficient cells for biochemical studies.
The generation of human osteoclasts in vitro has been a requirement to evaluate osteoclast pathophysiology in bone and calcium metabolism. Suda and co-workers (9, 10) had proposed a membrane-bound factor that would be expressed on osteoblasts/stromal cells in response to the stimulators of bone resorption and that induces osteoclastogenesis by signaling to osteoclast progenitors. Recently, several groups have succeeded in the molecular cloning of osteoclast differentiation factor (ODF), which mediates an essential signal for osteoclast differentiation from its precursor cells (11) . ODF was also found identical to tumor necrosis factorrelated activation-induced cytokine (TRANCE) (12) and receptor activator of nuclear factor-B ligand (RANKL) (13) . Using soluble (s) RANKL and macrophage colony-stimulating factor (M-CSF), Matsuzaki et al. (14) recently developed a new method to prepare human OCs from peripheral blood mononuclear cells, which enables study of the mechanisms that mediate the biological responses to CT in cells of human osteoclast lineage. In this manuscript, we describe the use of human OCs prepared in vitro, to study the regulation of CTR, information which is also important for the optimal use of CT therapy. We report the intriguing finding that the signaling pathway responsible for CTR down-regulation in human OCs is different from that in mouse OCs.
Materials and Methods Materials
Recombinant human sRANKL was purchased from PEPRO TECH EC Ltd. (London, UK). Recombinant human M-CSF was a kind gift from Morinaga Milk Ind. Co. Ltd. (Tokyo, Japan). Salmon CT (sCT), human CT (hCT), forskolin (FSK), dibutyryl cAMP (dbcAMP), calcium ionophore A23187, isobutylmethylxanthine (IBMX), trypsin-EDTA, ␣-MEM, and Histopaque 1077 were purchased from Sigma-Aldrich Corp. (St. Louis, MO). Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-didecanoate (PDD), and phorbol monoacetate (PA) were purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). cAMP assay kits were purchased from Yamasa Shoyu Co. (Chiba, Japan).
Preparation and culture of human OCs
Human OCs were prepared using a slight modification of the method reported by Matsuzaki et al. (14) . Briefly, peripheral blood was collected from healthy normal volunteers in syringes containing 1,000 U/ml of preservative-free heparin. Informed consent was obtained before blood aspiration. Mononuclear cells were isolated by centrifugation over Histopaque 1077 density gradients and resuspended at approximately 5.0 ϫ 10 6 cells/ml in ␣MEM supplemented with 10% FCS. The cells were then cultured for 7-14 days in 24-well plates (ϳ3.0 ϫ 10 6 cells/well) or 60-mm culture dishes (2.5 ϫ 10 7 cells/dish) in the presence of human sRANKL (100 ng/ml) and human M-CSF (200 ng/ml). Culture media were replenished with fresh media every 3-4 days. Cells were used for experiments when mature multinuclear cells were predominant in the cultures.
[ 125 
I]sCT binding experiments and tartrate-resistant acid phosphatase (TRAP) staining
Equal aliquots of OCs (ϳ3.0 ϫ 10 3 multinuclear OCs/well) were treated with CT or other agents for the times indicated. [
125 I]sCT with a specific activity of approximately 600 mCi/mg was purchased from Amersham Pharmacia Biotech Ltd. (Buckinghamshire, UK). OCs were incubated with CT or other agents in ␣MEM containing 10% FCS. Just before the binding experiments, cells were rinsed with acidified buffer (0.15 n NaCl/0.05 m glycine, pH 2.5, for 1 min) to remove CT, which binds to cell surface receptors, and rinsed thoroughly with cold PBS. Cells were then incubated with [
125 I]sCT (ϳ20,000 cpm/400 l; ϳ2 ϫ 10 Ϫ11 m) at 4 C for 4 h. Nonspecific binding was assessed by coincubation with 10 Ϫ6 m sCT. At the end of the incubation, cells were rinsed with cold PBS and dissolved in 0.5 n NaOH, and cell-bound radioactivity was measured. EC 50 was calculated from competitive binding studies with a fixed amount of [ 125 I]sCT and increasing amounts of unlabeled sCT. TRAP staining of the cells was as described previously (15) . In brief, cells were incubated for 20 min in 50 mm acetic acid buffer (pH 5.0) containing sodium tartrate dihydrate (50 mm), naphthol AS-MX phosphate (0.1 mg/ml), and fast red violet LB salt (0.6 mg/ml). After washing with distilled water and drying, the number of cells staining positive for TRAP was counted.
RNA extraction
Equal aliquots of OCs (ϳ3.0 ϫ 10 4 multinuclear OCs/dish) were treated with CT or other agents for the time indicated. After washing cells with cold PBS, total RNA was extracted by the acid guanidiniumphenol-chloroform method, as reported previously (16) .
PCR amplification of reverse transcribed messenger RNA (mRNA)
The RT of RNA to complementary DNA and the subsequent amplification were performed as described previously (6) . First-strand complementary DNA was synthesized from 1.0 g total RNA by incubation for 1 h at 42 C with 2.5 U/l MuLV reverse transcriptase, 2.5 m random hexamers, 1.0 U/l ribonuclease inhibitor, and 1.0 mm deoxynucleotide triphosphate mix. From this reaction mixture, 1 l of 20 l was submitted to PCR to amplify the sequence of the CTR mRNA specified below and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA in the OCs using GeneAmp RNA PCR Kit Components (PE Applied Biosystems, Foster City, CA). The reaction mixture, containing 100 pmol of each primer, 1.5 l 25-mm MgCl 2 solution, 2.5 l 10ϫ reaction buffer II, 5.0 U AmpliTaq DNA polymerase, and sterile distilled water, was overlaid with 50 l paraffin oil. Amplification was performed by TAKARA DNA Thermal cycler (TAKARA, Biotechnology, Kusatsu, Japan), with cycles of denaturation at 94 C for 1 min, annealing at 60 C for 1 min, and extension at 72 C for 1 min for CTR and GAPDH. Preliminary experiments were performed to ensure that the number of cycles employed was within the exponential phase of the amplification curve. PCR products were resolved on a 1.0% (wt/vol) agarose gel, and the specificity of the reaction was confirmed by Southern transfer to nylon filter (Hybond ϩ -N membrane, Amersham Pharmacia Biotech Ltd.) and hybridization with 32 P-labeled internal oligonucleotide probes. The signals were quantitated using an image analysis system (NIH image version 1.61).
Oligonucleotides used for this study were synthesized by Amersham Pharmacia Biotech). The oligonucleotides for human CTR were hCTR1, 5Ј-GCAATGCTTTCACTCCTGAGAAAC-3Ј (5Ј-primer); and hCTR2, 5Ј-CAGTAAACACAGCCACGACAATGAG-3Ј (3Ј-primer). The products were verified with the internal sense strand oligonucleotide, 5Ј-GTT-GAAGTAGTACCCAATGGA-3Ј (hCTR3) by Southern hybridization. To ensure equal starting quantities of DNA for the experiments and to allow semiquantitation of the PCR products representing CTR, reverse transcribed RNA samples were also amplified using oligonucleotide primers specific for human GAPDH sequence. Oligonucleotides for GAPDH were GAPDH3, 5Ј-CACTGACACGTTGGCAGTGG-3Ј (3Ј-primer); and GAPDH4, 5Ј-CATGGAGAAGGCTGGGGCTC-3Ј (5Ј-primer). PCR products were verified with a 32 P-labeled internal sense oligonucleotide GAPDH1, 5Ј-GCTGTGGGCAAGGTCATCCC-3Ј.
Bone resorption assay
Bone resorption (pit formation on dentine slices) was assayed as reported previously (17) . On days 7-8, OCs in 60-mm dishes (ϳ3.0 ϫ 10 4 multinuclear OCs/dish) were treated with 0.25% trypsin-EDTA for 10 min. OCs adherent to culture dishes were gently removed by sterile scrapers (Costar, Cambridge, MA). Cells were rinsed with PBS, and equal numbers of the cells (ϳ1000 multinuclear OCs/dentine slice) were resuspended onto dentine slices (4-mm diameter; ϳ200-m thick) in ␣MEM containing 10% FCS, sRANKL (100 ng/ml), and M-CSF (200 ng/ml) with CT or other agents, as specified. After incubation for 48 h, dentine slices were sonicated to remove the adherent cells in 1.0 n NH 4 OH. Slices were stained with Mayer's Hematoxylin solution (Wako Pure Chemical Industries Ltd.) for 2 min, rinsed with distilled water, and then air-dried. Resorption pits visualized by this staining were identified by light microscopy. The total pit areas were measured in four randomly selected areas of each dentine slice using an image analysis system (NIH image version 1.61).
Measurement of cAMP production
OCs (ϳ3.0 ϫ 10 3 multinuclear OCs/well) were treated with CT or other agents in ␣MEM containing 0.1% BSA and 1.0 mm IBMX for 20 min at 37 C. Cellular cAMP production was measured by RIA using a Yamasa RIA kit. Details of this assay were described in a previous report (18) .
Statistical analysis
Experimental data were analyzed using one-way ANOVA with post hoc Bonferroni-Dunn test.
Results

Effects of CT treatment on [ 125 I]sCT binding in human OCs
In mouse OCs, reduced sensitivity to CT was closely associated with homologous down-regulation of the CTR (6); and in human giant cell tumors, treatment with CT reduced CTR mRNA expression (7) . To examine more closely the effects of CT in normal human OCs, cells were treated with various concentrations of sCT and hCT, and then receptor binding capacity was measured. To determine total cell surface CTR, receptor-bound CT was removed by washing cells with isotonic acidified buffer, which we have previously shown removes CT from CTR in mouse OCs without affecting cellular viability (8, 19) . This method was originally reported for epidermal growth factor binding studies by Haigler et al. (20) . In human OCs, we also found that acid washing can effectively remove CT from its binding sites (Table 1) (Fig. 2) . Cell numbers, both mono-and multinuclear cells, were the same in sCT-treated and control groups (data not shown).
Effects of CT treatment on CTR mRNA expression in human OCs
To examine the action of CT on CTR mRNA expression, we applied a semiquantitative RT-PCR procedure. For the PCR, between 15-35 (the actual cycle number we used for PCR in the following experiments was 32) cycles of amplification were optimal for semiquantitative analysis of mRNA expression for CTR, and between 10 -25 (the actual cycle number we used for PCR in the following experiments was 20) cycles were optimal for GAPDH. The amplification was in the exponential phase over these ranges. OCs were treated with sCT for the indicated times, and RNA was extracted from the cells. OCs treated with sCT (10 Ϫ9 m) for up to 48 h showed a marked decrease of CTR mRNA expression in a time-dependent fashion (Fig. 3 ). Significant reduction of mRNA expression was observed 12 h after treatment with CT, with no recovery of mRNA expression observed over the experimental period. Experiments with cloned human (21), rat (22) , and porcine (23, 24) CTR have shown that these receptors are capable of coupling to at least two distinct G protein-mediated intracellular signaling pathways, to elevate intracellular Ca 2ϩ and activate PKC, and to elevate intracellular cAMP and activate PKA-mediated pathways. To investigate the intracellular signal transduction pathways that mediate homologous CTR down-regulation and the associated decrease of CTR mRNA expression in human OCs, we examined the effects of activation of PKA, PKC, and Ca 2ϩ -calmodulin dependent kinases. The active phorbol esters (PMA and PDD) directly activate PKC (25) , whereas the inactive analog PA is incapable of activating the kinase in these cells. To examine the role of the PKA pathway, we used FSK, a direct activator of the catalytic unit of adenylate cyclase (26) and the cAMP analog, dbcAMP. The calcium ionophore (A23187) can elevate intracellular Ca 2ϩ and lead to activation of Ca 2ϩ -calmodulin-dependent signaling. As shown in Fig. 4 -calmodulin-dependent kinase (A23187) significantly affected CTR mRNA expression (Fig. 5) .
Effects of activation of PKA, PKC, and Ca 2ϩ -calmodulindependent kinase on bone-resorbing activity (pit formation) in human OCs
In mouse OCs, Suzuki et al. (27) clearly showed that the effect of CT to inhibit bone resorption was predominantly mediated by PKA pathways, whereas the cellular signaling responsible for the process in humans has not been fully investigated. We therefore designed experiments to clarify the intracellular signaling pathways involved in the inhibition of osteoclastic resorption by CT. When the OCs were removed by trypsin from the dishes and then recultured, OCs were still positive for TRAP staining, but they only showed a very minimal resorptive activity in the absence of sRANKL and M-CSF. In this study, therefore, mature OCs were subcultured in growth media containing sRANKL (100 ng/ml) and M-CSF (200 ng/ml), for 48 h, in the absence or presence of sCT (10 Ϫ9 m), PMA (10 Ϫ7 m), PDD (10 Ϫ7 m), FSK (10 Ϫ5 m), dbcAMP (10 Ϫ4 m), and A23187 (10 Ϫ7 m) (ϳ1000 multinuclear OCs/dentine slice). Subsequently the resorbed areas of bone were quantitated, as described in Materials and Methods. The number of cells was assessed by TRAP staining and was not changed by these treatments. Treatment of OCs for 48 h with PKA activators (FSK and dbcAMP) or with OCs/dish). OCs were treated with sCT (10 Ϫ9 M) for 4 -48 h, and total RNA was extracted. RNA was reverse transcribed and subjected to PCR in 32 cycles for CTR mRNA amplification and 20 cycles for GAPDH amplification, using specific primers, as described in Materials and Methods. PCR products were transferred to a nylon filter and hybridized with 32 P-labeled hCTR3, an internal sense oligonucleotide specific to human CTR sequence, and 32 P-labeled GAPDH1, specific to human GAPDH sequence. The intensities of autoradiograph signals were quantitated and are shown below as the ratio of CTR/GAPDH compared with control (the value of 1.0). Each point represents the mean Ϯ SD for four PCR products. *, P Ͻ 0.01 vs. control cells. This figure is representative of four separate experiments; similar results were obtained in the other three experiments. Cont, Control. A23187 did not inhibit osteoclastic bone-resorbing activity. In contrast, treatment with active phorbols (PMA and PDD) for 48 h inhibited the bone-resorbing function of OCs (Fig. 6) .
FIG. 4. Effects of activators of PKC
Recovery of [ 125 l]sCT binding capacity and CTR mRNA expression after preincubation of sCT in human OCs
As reported previously (6, 17, 28) , even brief treatment with CT affects osteoclast activity for a prolonged period. Using a mouse coculture system, it was reported that the recovery of CTR mRNA and CT binding was not observed until 72 h after short CT treatment (28) . However, there is scant information on when and how osteoclasts regain their responsiveness to CT. In this study, we applied a method of coincubation with sRANKL(100 ng/ml) and M-CSF (200 ng/ ml), which not only generates OCs from peripheral blood mononuclear cells but also elongates the survival of mature OCs (29) . This procedure enables investigation of biochemical features of OCs in culture for prolonged periods. When the OCs were treated with sCT (10 Ϫ9 m) for 1 h and then rinsed, binding capacity for [
125 I] sCT was decreased, as shown in Fig. 7 . The sCT-treated OCs, however, regained binding capacity toward the level of control cells by 96 h after sCT removal. Under the conditions of the experiments reported here, CT treatment had no statistically significant effect on the number of mononuclear or multinuclear OCs. Furthermore, nucleus number per multinucleated cells did not differ significantly between treated and control cells (Fig. 7) .
Effects of CT on CTR mRNA expression were also evaluated by short exposure to sCT in the OCs. OCs were treated with sCT (10 Ϫ9 m, 1 h), rinsed thoroughly with PBS, and further cultured in the growth media containing sRANKL and M-CSF. The total RNA was extracted, at each time point, as described in Materials and Methods. Reduced expression of CTR mRNA was observed around 24 -48 h after removal sCT, but the expression of the mRNA returned toward control levels by 72 h after removal of sCT (Fig. 8) . M), and A23187 (10 Ϫ7 M), for 24 h, in ␣MEM containing 10% FCS. After washing with PBS, total RNA was extracted. RNA was reverse transcribed and subjected to 32 cycles of PCR for CTR mRNA amplification and 20 cycles for GAPDH amplification using specific primers, as described in Materials and Methods. PCR products were transferred to a nylon filter and hybridized with 32 P-labeled hCTR3, an internal sense oligonucleotide specific to the CTR sequence, and 32 P-labeled GAPDH1, specific to the GAPDH sequence. Signals were quantitated and are shown in the lower panel as the ratio of CTR/GAPDH PCR products compared with control (the value of 1.0). Each point represents the mean Ϯ SD for four PCR products. *, P Ͻ 0.01 vs. control cells. This figure is representative of three separate experiments in which similar results were obtained.
FIG. 6. Effects of activators of PKA, PKC, and Ca
2ϩ -calmodulindependent kinase on pit formation of human OCs. OCs on plastic dishes were treated with 0.25% trypsin-EDTA for 10 min and gently removed with scrapers, and equal numbers of OCs were settled onto dentine slices (ϳ1000 multinuclear OCs/dentine slice). After settlement, the OCs were cultured with sCT (10 Ϫ9 M), PMA (10 Ϫ7 M), PDD (10 Ϫ7 M), FSK (10 Ϫ5 M), dbcAMP (10 Ϫ4 M), and A23187 (10 Ϫ7 M) in growth media containing 10% FCS, sRANKL (100 ng/ml), and M-CSF (200 ng/ml) for 48 h. The area of bone resorbed was quantitated as described in Materials and Methods. Each point represents the mean Ϯ SD of four random fields. *, P Ͻ 0.01 vs. control cells. This figure is representative of three separate experiments in which similar results were obtained. Bar, 200 m.
cAMP responses to CT rechallenge in human OCs
To investigate the recovery process and sensitivity to CT rechallenge in the OCs, we measured cAMP production in CT-pretreated OCs. OCs were pretreated with sCT (10 Ϫ9 m) for 1 h, rinsed thoroughly with PBS, and cultured with fresh growth media containing sRANKL and M-CSF. Basal and sCT (10 Ϫ9 m)-stimulated cAMP production was measured on days 0, 1, 4, and 7 after removal of sCT. In control cells, treatment with CT in OCs increased adenylate cyclase response, as shown in Fig. 9 . Twenty-four hours after the removal of sCT, OCs showed desensitization to a rechallenge with sCT. Ninety-six hours after the removal of sCT, responsiveness to CT returned. However, full responsiveness of sCT-pretreated OCs to the rechallenge with CT required longer than 96 h and was seen at 7 days after removal of sCT (Fig. 9) .
Discussion
This study confirms our earlier work, where we found that treatment of OCs with CT induced prolonged homologous CTR down-regulation, decline in CTR mRNA expression, and desensitization of CT-stimulated adenylate cyclase activity (6). Concentrations of sCT or hCT, which did not acutely reduce CTR binding capacity, could nevertheless induce homologous down-regulation of the CTR. In the present work, we applied an acid pH washing procedure to exclude the possibility that continuous treatment with CT for 24 h simply occupied cell surface CTR rather than decreasing their concentration. Along with reduced CTR mRNA expression, a decreased receptor number after acid washing clearly indicated that the decreased de novo CTR synthesis is responsible for the homologous CTR down-regulation in human OCs. The mechanisms of homologous down-regulation of peptide hormone receptors have been studied in 4 multinuclear OCs/dish). OCs were treated with sCT (10 Ϫ9 M) for 1 h. After removal of the media, cells were thoroughly rinsed with PBS and further incubated up to 7 days with fresh growth media containing 10% FCS, sRANKL (100 ng/ml), and M-CSF (200 ng/ml). Total RNA was extracted at each time point. RNA was reverse transcribed and subjected to 32 cycles of PCR for CTR mRNA amplification and 20 cycles for GAPDH amplification using specific primers, as described in Materials and Methods. PCR products were transferred to a nylon filter and hybridized with 32 Plabeled hCTR3, an internal sense oligonucleotide specific to hCTR sequence, and 32 P-labeled GAPDH1, specific to GAPDH sequence. various cells and tissues. In general, the number of functional receptors expressed on the cell surface is regulated by several mechanisms, including modulation of receptor expression, partitioning of functional receptors between the cell surface and internal pools (sequestration), and degradation of receptor protein. Experiments to explore the molecular basis of the CTR gene expression in osteoclasts suggested that CT down-regulate CTR by inhibiting transcription of CTR gene expression (30) and/or by reducing stability of CTR mRNA (31) . The effect of CT on CTR mRNA stability in mouse OCs required ongoing transcription, suggesting the involvement of a labile protein mRNA-degrading factor. The AUUUA motifs, as well as other A/U-rich sequences, have been shown to determine the stability of other mRNA transcripts through binding with multiple proteins in this region (32) . Multiple copies of the AUUUA motif have been identified in the 3Ј untranslated regions of CTR gene in various species (31) , including the human (33) .
The mechanism of CTR regulation has been studied in clonal cells, in which evidence was consistent with rapid ligand-induced internalization of the CT-CTR complex and persistent activation of adenylate cyclase by CT treatment (19, 34, 35) . Similar results have been observed in rat and mouse osteoclasts (4, 6) , suggesting that the basic relationships of ligand-receptor interactions of CT are conserved among cell types and different species. The results obtained from the studies of cells transfected with clonal CTR showed that CTRs couple to effector systems that lead to activation of PKA, PKC, and pathways mediated by elevation of intracellular Ca 2ϩ (21) (22) (23) (24) . Although transfected studies are beneficial to understanding basic receptor biology, e.g. receptor-ligand recognition and subsequent induction of intracellular events, there is a potential limitation that they may not always reflect all aspects of receptor biology, such as physiological receptor regulation, as they occur in target cells. Osteoclasts, the main target cells of CT in bone, respond to CT very differently from the model cell systems: CT induces retraction of osteoclasts and inhibits osteoclastic boneresorbing activity (36) , although some of the important aspects would be conserved irrespective of the cell types (37) .
In the present study, treatment of OCs with activators of PKC mimicked the effect of CT on CTR down-regulation and CTR mRNA expression, whereas neither activation of PKA nor elevation of intracellular Ca 2ϩ did so. These data suggest that the PKC pathway is primarily involved in homologous down-regulation of the CTR in human OCs. The effect of CT on inhibition of bone resorption was also found to be mediated predominantly through a PKC-dependent signaling pathway in the cells (Fig. 6) . In rat osteoclasts, the inhibitory effect of CT was shown to be mediated by both PKA-and PKC-mediated signaling (36, 38) : activation of the PKC pathway induced rapid osteoclast retraction, and that of the PKA pathway inhibited subsequent osteoclast motility. In mouse OCs, it was shown, however, that CT inhibition of F-actin ring formation and bone resorption was mediated by PKA rather than PKC-mediated signaling (27) , results which were also consistent with our work on the intracellular signaling responsible for homologous CTR regulation in mouse OCs (8) . The results obtained in human OCs were contrary to those studies: the action of CT on human OCs seem to occur predominantly through activation of a PKC-dependent cascade, leading to homologous CTR down-regulation and inhibition of bone resorption. It has been demonstrated that peptide hormones act on target tissues in cell-and speciesspecific ways in various experimental models. In brain tissue, CT apparently causes either no change, or an inhibition, of adenylate cyclase activity (39) . Nevertheless, CTRs cloned from brain are capable of coupling to stimulatory GTP-binding protein when they are expressed in other cell types (22) . In hepatocytes, CT prevented CCl4-induced oxyradical formation and cellular damage by a mechanism involving activation of PKC (40) . In LLC-PK1 pig kidney cells, intracellular signaling varied in a cell cycle-dependent manner (41) . It was shown recently that CT induced Shc phosphorylation and activation of Erk1/2, a serine/threonine PK in human embryonic kidney cells transfected with C1a isoform of the rabbit CTR (42) . CT also phosphorylated human enhancer of filamentation 1 (HEF1), a p130
Cas -like docking protein, which is involved in the modulation of cell attachment and cytoskeletal function (37) . These signaling networks were found to be the downstream target of PKC and an elevation of intracellular Ca 2ϩ but were largely independent of PKA (37, 42) .
CT has been used to treat malignancy-associated hypercalcemia, Paget's disease of bone and osteoporosis (1-3). Usage of CT in osteoporotic patients varies among the protocols: daily CT, given intranasally (43, 44) or im (45, 46) , has shown its efficacy for treatment, whereas the other studies showed that im injection of CT only once or twice a week could achieve significant improvement of bone mineral density (47) . It has been shown, however, that the effects of CT were diminished by repetitive administration, which has been shown in earlier clinical studies (48) , as well as in vitro studies (49) . Although CT potently inhibits osteoclastic boneresorbing activity, OCs exposed to CT showed resistance or refractoriness to the rechallenge with CT, which was parallel to the homologous CTR down-regulation (6) . There are also some reports showing that the generation of neutralizing antibodies to CT may relate to the refractoriness to the rechallenge with CT (50), although the contribution of antibodies to the so-called escape phenomenon remains to be fully elucidated. Because it had been difficult to culture osteoclasts for a long period of time, recovery of cell surface CTR expression and changes of sensitivity to CT rechallenge have not been examined in osteoclasts. Jimi et al. (29) recently found that treatment with sRANKL and M-CSF could maintain viability of OCs and elongate survival of the cells. In the presence of sRANKL and M-CSF, the OCs pretreated with CT were cultured up to 14 days, to examine biochemical features of CTR. When human OCs were treated with sCT (10 Ϫ9 m) for 1 h and then rinsed, binding capacity for [ 125 I] sCT was immediately reduced, but the binding capacity gradually returned toward the level of control cells by 96 h after sCT removal (Fig. 7) . The recovery was also confirmed at the level of CTR mRNA expression and CT-sensitive adenylate cyclase responses. These results indicated that OCs pretreated with CT could regain responsiveness to CT rechallenge eventually. Intermittent administration of CT might be effective to attenuate desensitization to CT, which occurred in CT target tissues.
In conclusion, this study shows that the intracellular signaling pathway responsible for homologous regulation of CTR and inhibition of osteoclastic bone resorption in human OCs is the PKC pathway. Our results also suggest that, in human OCs, even short exposure to CT induced prolonged desensitization to CT rechallenge, which recovers gradually. This may suggest that intermittent administration of CT would be effective for the treatment of osteoporosis, resulting in reduced desensitization in CT target cells.
